Add-on tofacitinib shows treatment promise in SSc-ILD
The addition of tofacitinib to conventional disease-modifying antirheumatic drugs could help alleviate sclerosis in patients with systemic sclerosis-associated interstitial lung disease, suggests research.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
